Evaluation of nafamostat mesilate as an alternative anticoagulant during intermittent hemodialysis in healthy Beagle dogs

Joon hyuk Choi, Seok yeong Byun, Aryung Nam, Sei myoung Han, Kyu pil Lee, Kun ho Song, Hwa young Youn, Kyoung Won Seo

Research output: Contribution to journalArticle

Abstract

Objective: To evaluate nafamostat mesilate (NM) as an alternative anticoagulant agent for intermittent hemodialysis (IHD). Design: Prospective randomized study. Setting: University teaching hospital. Animals: Eighteen healthy Beagle dogs. Interventions: In group 1 (n = 6), NM was administered at a dose of 0.5 mg/kg/h during IHD for 5 hours. In group 2 (n = 6), NM was administered at a low dose of 0.25 mg/kg/h during IHD. In group 3 (n = 6), which was the control group, unfractionated heparin (UFH) was administered during IHD. The evaluated parameters included: the amount of residual blood clots in the blood chamber and arterial side of the dialyzer; the levels of hemoglobin, hematocrit, and platelets; and the prothrombin time (PT), activated partial thromboplastin time (aPTT), and activated clotting time (ACT). Measurements and Main Results: Groups 1 and 2 successfully completed IHD without serious coagulation in the extracorporeal circulation. The residual blood clotting in the blood chamber and arterial side of the dialyzer did not significantly differ in groups 1 and 2 compared to group 3 (group 1 vs group 3, P = 1.000; and group 2 vs group 3, P = 1.000). No significant differences were observed between pre- and posttreatment PTs in groups 1 (P = 0.476) and 2 (P = 0.597), between pre- and posttreatment aPTTs in groups 1 (P = 0.983) and 2 (P = 0.977), and between pre- and posttreatment ACT in groups 1 (P = 0.282) and 2 (P = 0.401). In group 3, a significant elevation of ACT was observed at the posttest (P < 0.001). Conclusions: The results of this study in healthy Beagle dogs suggest that NM at 0.25 mg/kg/h may be a valid alternative to UFH for IHD. Further studies are needed in patients at high risk of bleeding.

Original languageEnglish (US)
JournalJournal of Veterinary Emergency and Critical Care
DOIs
StateAccepted/In press - Jan 1 2018
Externally publishedYes

Fingerprint

hemodialysis
anticoagulants
Beagle
Anticoagulants
Renal Dialysis
Dogs
dogs
pretreatment
heparin
Heparin
blood
thromboplastin
blood coagulation
prothrombin
Extracorporeal Circulation
Partial Thromboplastin Time
Prothrombin Time
Blood Coagulation
dosage
coagulation

Keywords

  • Anticoagulation
  • Canine
  • Dialysis
  • Extracorporeal therapy
  • Kidney injury
  • Unfractionated heparin

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Evaluation of nafamostat mesilate as an alternative anticoagulant during intermittent hemodialysis in healthy Beagle dogs. / Choi, Joon hyuk; Byun, Seok yeong; Nam, Aryung; Han, Sei myoung; Lee, Kyu pil; Song, Kun ho; Youn, Hwa young; Seo, Kyoung Won.

In: Journal of Veterinary Emergency and Critical Care, 01.01.2018.

Research output: Contribution to journalArticle

Choi, Joon hyuk ; Byun, Seok yeong ; Nam, Aryung ; Han, Sei myoung ; Lee, Kyu pil ; Song, Kun ho ; Youn, Hwa young ; Seo, Kyoung Won. / Evaluation of nafamostat mesilate as an alternative anticoagulant during intermittent hemodialysis in healthy Beagle dogs. In: Journal of Veterinary Emergency and Critical Care. 2018.
@article{668d612e27124be8b3ed3781281c4644,
title = "Evaluation of nafamostat mesilate as an alternative anticoagulant during intermittent hemodialysis in healthy Beagle dogs",
abstract = "Objective: To evaluate nafamostat mesilate (NM) as an alternative anticoagulant agent for intermittent hemodialysis (IHD). Design: Prospective randomized study. Setting: University teaching hospital. Animals: Eighteen healthy Beagle dogs. Interventions: In group 1 (n = 6), NM was administered at a dose of 0.5 mg/kg/h during IHD for 5 hours. In group 2 (n = 6), NM was administered at a low dose of 0.25 mg/kg/h during IHD. In group 3 (n = 6), which was the control group, unfractionated heparin (UFH) was administered during IHD. The evaluated parameters included: the amount of residual blood clots in the blood chamber and arterial side of the dialyzer; the levels of hemoglobin, hematocrit, and platelets; and the prothrombin time (PT), activated partial thromboplastin time (aPTT), and activated clotting time (ACT). Measurements and Main Results: Groups 1 and 2 successfully completed IHD without serious coagulation in the extracorporeal circulation. The residual blood clotting in the blood chamber and arterial side of the dialyzer did not significantly differ in groups 1 and 2 compared to group 3 (group 1 vs group 3, P = 1.000; and group 2 vs group 3, P = 1.000). No significant differences were observed between pre- and posttreatment PTs in groups 1 (P = 0.476) and 2 (P = 0.597), between pre- and posttreatment aPTTs in groups 1 (P = 0.983) and 2 (P = 0.977), and between pre- and posttreatment ACT in groups 1 (P = 0.282) and 2 (P = 0.401). In group 3, a significant elevation of ACT was observed at the posttest (P < 0.001). Conclusions: The results of this study in healthy Beagle dogs suggest that NM at 0.25 mg/kg/h may be a valid alternative to UFH for IHD. Further studies are needed in patients at high risk of bleeding.",
keywords = "Anticoagulation, Canine, Dialysis, Extracorporeal therapy, Kidney injury, Unfractionated heparin",
author = "Choi, {Joon hyuk} and Byun, {Seok yeong} and Aryung Nam and Han, {Sei myoung} and Lee, {Kyu pil} and Song, {Kun ho} and Youn, {Hwa young} and Seo, {Kyoung Won}",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/vec.12696",
language = "English (US)",
journal = "Journal of Veterinary Emergency and Critical Care",
issn = "1479-3261",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Evaluation of nafamostat mesilate as an alternative anticoagulant during intermittent hemodialysis in healthy Beagle dogs

AU - Choi, Joon hyuk

AU - Byun, Seok yeong

AU - Nam, Aryung

AU - Han, Sei myoung

AU - Lee, Kyu pil

AU - Song, Kun ho

AU - Youn, Hwa young

AU - Seo, Kyoung Won

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objective: To evaluate nafamostat mesilate (NM) as an alternative anticoagulant agent for intermittent hemodialysis (IHD). Design: Prospective randomized study. Setting: University teaching hospital. Animals: Eighteen healthy Beagle dogs. Interventions: In group 1 (n = 6), NM was administered at a dose of 0.5 mg/kg/h during IHD for 5 hours. In group 2 (n = 6), NM was administered at a low dose of 0.25 mg/kg/h during IHD. In group 3 (n = 6), which was the control group, unfractionated heparin (UFH) was administered during IHD. The evaluated parameters included: the amount of residual blood clots in the blood chamber and arterial side of the dialyzer; the levels of hemoglobin, hematocrit, and platelets; and the prothrombin time (PT), activated partial thromboplastin time (aPTT), and activated clotting time (ACT). Measurements and Main Results: Groups 1 and 2 successfully completed IHD without serious coagulation in the extracorporeal circulation. The residual blood clotting in the blood chamber and arterial side of the dialyzer did not significantly differ in groups 1 and 2 compared to group 3 (group 1 vs group 3, P = 1.000; and group 2 vs group 3, P = 1.000). No significant differences were observed between pre- and posttreatment PTs in groups 1 (P = 0.476) and 2 (P = 0.597), between pre- and posttreatment aPTTs in groups 1 (P = 0.983) and 2 (P = 0.977), and between pre- and posttreatment ACT in groups 1 (P = 0.282) and 2 (P = 0.401). In group 3, a significant elevation of ACT was observed at the posttest (P < 0.001). Conclusions: The results of this study in healthy Beagle dogs suggest that NM at 0.25 mg/kg/h may be a valid alternative to UFH for IHD. Further studies are needed in patients at high risk of bleeding.

AB - Objective: To evaluate nafamostat mesilate (NM) as an alternative anticoagulant agent for intermittent hemodialysis (IHD). Design: Prospective randomized study. Setting: University teaching hospital. Animals: Eighteen healthy Beagle dogs. Interventions: In group 1 (n = 6), NM was administered at a dose of 0.5 mg/kg/h during IHD for 5 hours. In group 2 (n = 6), NM was administered at a low dose of 0.25 mg/kg/h during IHD. In group 3 (n = 6), which was the control group, unfractionated heparin (UFH) was administered during IHD. The evaluated parameters included: the amount of residual blood clots in the blood chamber and arterial side of the dialyzer; the levels of hemoglobin, hematocrit, and platelets; and the prothrombin time (PT), activated partial thromboplastin time (aPTT), and activated clotting time (ACT). Measurements and Main Results: Groups 1 and 2 successfully completed IHD without serious coagulation in the extracorporeal circulation. The residual blood clotting in the blood chamber and arterial side of the dialyzer did not significantly differ in groups 1 and 2 compared to group 3 (group 1 vs group 3, P = 1.000; and group 2 vs group 3, P = 1.000). No significant differences were observed between pre- and posttreatment PTs in groups 1 (P = 0.476) and 2 (P = 0.597), between pre- and posttreatment aPTTs in groups 1 (P = 0.983) and 2 (P = 0.977), and between pre- and posttreatment ACT in groups 1 (P = 0.282) and 2 (P = 0.401). In group 3, a significant elevation of ACT was observed at the posttest (P < 0.001). Conclusions: The results of this study in healthy Beagle dogs suggest that NM at 0.25 mg/kg/h may be a valid alternative to UFH for IHD. Further studies are needed in patients at high risk of bleeding.

KW - Anticoagulation

KW - Canine

KW - Dialysis

KW - Extracorporeal therapy

KW - Kidney injury

KW - Unfractionated heparin

UR - http://www.scopus.com/inward/record.url?scp=85041657287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041657287&partnerID=8YFLogxK

U2 - 10.1111/vec.12696

DO - 10.1111/vec.12696

M3 - Article

C2 - 29419934

AN - SCOPUS:85041657287

JO - Journal of Veterinary Emergency and Critical Care

JF - Journal of Veterinary Emergency and Critical Care

SN - 1479-3261

ER -